Phase III Trial for COVID-19 and COVID-like Treatment
(374 / 999 enrolled as of June 2025)
SaNOtize and ECRAID-Prime are collaborating in Europe’s adaptive primary-care platform trial to evaluate Nitric Oxide Nasal Spray (NONS) for respiratory infections. This Phase IIb study compares NONS versus intranasal saline, and saline versus usual care, in participants with COVID-19 or COVID-like illness. The trial spans 28 sites across eight European countries: Belgium, France, Germany, Ireland, Poland, Spain, Georgia, and the UK.
Details: ECRAID-Prime NONS Trial | Ecraid
Retrospective Study for COVID-19 Prevention After Exposure
In a quarantine‐based study of 625 university students in Thailand exposed to Omicron, 203 opted to use NONS™ (four sprays per nostril, four times daily) and 422 did not. The infection rate was 6.4% with NONS™ versus 25.6% in controls (P < 0.0001), a 75% risk reduction.
Results: Epidemiological Analysis of NONS™ Use in Exposed Students
Phase III Trial for COVID-19 Treatment
This randomized, double-blind, placebo-controlled study at 20 sites in India enrolled 306 COVID-19 patients. NONS™ reduced viral load by >94% in the first 24 hours and >99% by 48 hours, compared with saline spray. Median time to negative PCR was four days versus eight days in placebo.
Published in The Lancet Regional Health – Southeast Asia: SARS-CoV-2 accelerated clearance using a novel NONS™ treatment: A randomized trial | Download PDF
Phase II Trial for COVID-19 Treatment
In a UK trial of 80 early COVID-19 cases, NONS™ (5–6 sprays/day for 9 days) led to a 95% average viral load reduction in 24 hours and >99% by 72 hours versus placebo. Symptom resolution was also faster with NONS™.
Published in the Journal of Infection: Clinical efficacy of NONS™ for treatment of mild COVID-19 infection | Download PDF